Neurocrine Biosciences Announces Publication of Expert Recommendations for Glucocorticoid Dose Reduction after Initiating CRENESSITY® (crinecerfont) for the Treatment of Classic Congenital Adrenal Hyperplasia
Wednesday, May 6, 2026 1 min read
Key Takeaway: Neurocrine Biosciences has published the first peer-reviewed expert recommendations for glucocorticoid dose reduction in patients with classic congenital adrenal hyperplasia treated with CRENESSITY (crinecerfont). This publication, featured in The Journal of Clinical Endocrinology & Metabolism, aims to address a critical unmet need as the drug's use expands among both pediatric and adult patients.
Market Sentiment Analysis
Full Press Release Details
SAN DIEGO,May 6, 2026/PRNewswire/ --Neurocrine Biosciences, Inc.(Nasdaq:NBIX) today announced the publication of the first peer-reviewed expert recommendations to guide glucocorticoid dose reduction in patients with classic congenital adrenal hyperplasia treated withCRENESSITY®(crinecerfont). Published inThe Journal of Clinical Endocrinology & Metabolism,the recommendations address a critical unmet need as real-world use of CRENESSITY expands in both pediatric and adult patients.
Frequently Asked Questions
What is CRENESSITY used for?
CRENESSITY (crinecerfont) is used for treating classic congenital adrenal hyperplasia.
Where were the expert recommendations published?
The recommendations were published in The Journal of Clinical Endocrinology & Metabolism.
Who benefits from the new recommendations?
The recommendations benefit both pediatric and adult patients with congenital adrenal hyperplasia.
What is the significance of these recommendations?
They address a critical unmet need for glucocorticoid dose reduction in treatment.